The rationale for pharmacologic therapy in stable chronic obstructive pulmonary disease

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The structural changes in airways and alveoli that characterize chronic obstructive pulmonary disease (COPD) result from an abnormal and persistent inflammatory reaction to inhaled noxious particles or gases, notably tobacco smoke. This remodeling of the lung leads to irreversible airflow obstruction. However, COPD should be viewed by clinicians as a treatable condition, since most patients with COPD have an additional reversible component related to increased bronchomotor tone. The use of bronchodilators, especially anticholinergics and β2-agonists, results in a reduction in airway smooth muscle tone and airflow resistance; this translates into marked improvement in significant clinical outcomes such as dyspnea, quality of life, and exercise capacity. An increasing amount of evidence supports the idea that long-acting agents have more significant impact in these parameters than the short-acting preparations.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalAmerican Journal of the Medical Sciences
Volume329
Issue number4
DOIs
StatePublished - Apr 1 2005

Fingerprint

Chronic Obstructive Pulmonary Disease
Bronchodilator Agents
Cholinergic Antagonists
Smoke
Dyspnea
Tobacco
Smooth Muscle
Therapeutics
Gases
Quality of Life
Exercise
Lung

Keywords

  • Anticholinergics
  • Beta-agonists
  • Chronic obstructive pulmonary disease
  • Pharmacotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{725f979b71884b278c7f6cc77a5134cd,
title = "The rationale for pharmacologic therapy in stable chronic obstructive pulmonary disease",
abstract = "The structural changes in airways and alveoli that characterize chronic obstructive pulmonary disease (COPD) result from an abnormal and persistent inflammatory reaction to inhaled noxious particles or gases, notably tobacco smoke. This remodeling of the lung leads to irreversible airflow obstruction. However, COPD should be viewed by clinicians as a treatable condition, since most patients with COPD have an additional reversible component related to increased bronchomotor tone. The use of bronchodilators, especially anticholinergics and β2-agonists, results in a reduction in airway smooth muscle tone and airflow resistance; this translates into marked improvement in significant clinical outcomes such as dyspnea, quality of life, and exercise capacity. An increasing amount of evidence supports the idea that long-acting agents have more significant impact in these parameters than the short-acting preparations.",
keywords = "Anticholinergics, Beta-agonists, Chronic obstructive pulmonary disease, Pharmacotherapy",
author = "Campos, {Michael A} and Adam Wanner",
year = "2005",
month = "4",
day = "1",
doi = "10.1097/00000441-200504000-00004",
language = "English",
volume = "329",
pages = "181--189",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The rationale for pharmacologic therapy in stable chronic obstructive pulmonary disease

AU - Campos, Michael A

AU - Wanner, Adam

PY - 2005/4/1

Y1 - 2005/4/1

N2 - The structural changes in airways and alveoli that characterize chronic obstructive pulmonary disease (COPD) result from an abnormal and persistent inflammatory reaction to inhaled noxious particles or gases, notably tobacco smoke. This remodeling of the lung leads to irreversible airflow obstruction. However, COPD should be viewed by clinicians as a treatable condition, since most patients with COPD have an additional reversible component related to increased bronchomotor tone. The use of bronchodilators, especially anticholinergics and β2-agonists, results in a reduction in airway smooth muscle tone and airflow resistance; this translates into marked improvement in significant clinical outcomes such as dyspnea, quality of life, and exercise capacity. An increasing amount of evidence supports the idea that long-acting agents have more significant impact in these parameters than the short-acting preparations.

AB - The structural changes in airways and alveoli that characterize chronic obstructive pulmonary disease (COPD) result from an abnormal and persistent inflammatory reaction to inhaled noxious particles or gases, notably tobacco smoke. This remodeling of the lung leads to irreversible airflow obstruction. However, COPD should be viewed by clinicians as a treatable condition, since most patients with COPD have an additional reversible component related to increased bronchomotor tone. The use of bronchodilators, especially anticholinergics and β2-agonists, results in a reduction in airway smooth muscle tone and airflow resistance; this translates into marked improvement in significant clinical outcomes such as dyspnea, quality of life, and exercise capacity. An increasing amount of evidence supports the idea that long-acting agents have more significant impact in these parameters than the short-acting preparations.

KW - Anticholinergics

KW - Beta-agonists

KW - Chronic obstructive pulmonary disease

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=17244378879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17244378879&partnerID=8YFLogxK

U2 - 10.1097/00000441-200504000-00004

DO - 10.1097/00000441-200504000-00004

M3 - Article

VL - 329

SP - 181

EP - 189

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 4

ER -